MPO-ANCA Associated Vasculitis Following COVID-19 Vaccination – A Case Report

MPO-ANCA Associated Vasculitis Following COVID-19 Vaccination – A Case Report

Whether autoimmune or rheumatic disease can be precipitated after vaccination is controversial. Only epidemiological studies or clinical trials with an extremely large sample size can allow for a consistent assessment of the relative risk of vaccine-related incidence. Studies with such large sample...

Full description

Bibliographic Details
Main Authors:	Mahmoud Khalifa, Yara Adel Altahan, Paavana Varanasi
Format:	Article
Language:	English
Published:	Levy Library Press 2021-05-01
Series:	Journal of Scientific Innovation in Medicine
Subjects:	covid-19 vaccination mpo-anca vasculitis autoimmune sars-cov-2 covid-19
Online Access:	https://journalofscientificinnovationinmedicine.org/articles/101

Similar Items

Newly diagnosed ANCA-associated vasculitis after COVID-19 infection: a case report
by: Kazuhiro Kitamoto, et al.
Published: (2023-08-01)

Presentation and progression of MPO-ANCA interstitial lung disease
by: Lorenzo Salvati, et al.
Published: (2024-06-01)

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series
by: L. Caroti, et al.
Published: (2019-05-01)

Neutrophil Extracellular Traps: A Potential Therapeutic Target in MPO-ANCA Associated Vasculitis?
by: Kim M. O'Sullivan, et al.
Published: (2021-03-01)

MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination
by: Stefanie Eindhoven, et al.
Published: (2017-12-01)

Implication of platelets and complement C3 as link between innate immunity and tubulointerstitial injury in renal vasculitis with MPO-ANCA seropositivity
by: Eva Baier, et al.
Published: (2022-11-01)

ANCA-Associated Vasculitis May Result as a Complication to Both SARS-CoV-2 Infection and Vaccination
by: Michalis Christodoulou, et al.
Published: (2022-07-01)

Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis following COVID-19 BBIBP-CorV vaccine: A case report
by: Parisa Javadian, et al.
Published: (2024-01-01)

Systematic Histological Scoring Reveals More Prominent Interstitial Inflammation in Myeloperoxidase-ANCA Compared to Proteinase 3-ANCA Glomerulonephritis
by: Samy Hakroush, et al.
Published: (2021-03-01)

Dual-Positive MPO- and PR3-ANCA-Associated Vasculitis Following SARS-CoV-2 mRNA Booster Vaccination: A Case Report and Systematic Review
by: Eva Baier, et al.
Published: (2022-04-01)

New onset ANCA-associated vasculitis in an adolescent during an acute COVID-19 infection: a case report
by: Daniel D. Reiff, et al.
Published: (2021-08-01)

ANCA Associated Glomerulonephritis Following SARS-CoV-2 Vaccination: A Case Series and Systematic Review
by: Theerachai Thammathiwat, et al.
Published: (2023-05-01)

C-Reactive Protein Levels Are Associated with Complement C4 Deposits and Interstitial Arteritis in ANCA-Associated Renal Vasculitis
by: Peter Korsten, et al.
Published: (2023-02-01)

Acute PR3-ANCA vasculitis in an asymptomatic COVID-19 teenager
by: Taylor Wintler, et al.
Published: (2021-12-01)

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia: PR3-versus MPO-ANCA-associated vasculitis, an exploratory cross-sectional studyResearch in context
by: Charmaine van Eeden, et al.
Published: (2023-04-01)

Clinical characteristics and primary outcomes of patients with ANCA-associated vasculitis and central diabetes insipidus
by: Xin Chen, et al.
Published: (2023-05-01)

Comparative Histological Subtyping of Immune Cell Infiltrates in MPO-ANCA and PR3-ANCA Glomerulonephritis
by: Samy Hakroush, et al.
Published: (2021-10-01)

The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis
by: Christian Agosto‐Burgos, et al.
Published: (2022-01-01)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
by: Claire Harris, et al.
Published: (2018-06-01)

B Lineage Cells in ANCA-Associated Vasculitis
by: Ana Merino-Vico, et al.
Published: (2021-12-01)

Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2020-09-01)

New‐onset ANCA‐associated vasculitis presenting with neuropathy after COVID‐19 infection: A case report and literature review
by: Aida Mohamadi, et al.
Published: (2024-01-01)

ANCA-associated vasculitis in childhood: recent advances
by: Marta Calatroni, et al.
Published: (2017-05-01)

The potential pathogenic roles of S100A8/A9 and S100A12 in patients with MPO-ANCA-positive vasculitis
by: Xue Bai, et al.
Published: (2022-09-01)

BA.1/BA.5 Immunogenicity, Reactogenicity, and Disease Activity after COVID-19 Vaccination in Patients with ANCA-Associated Vasculitis: A Prospective Observational Cohort Study
by: Claudius Speer, et al.
Published: (2023-08-01)

ANCA-Associated Vasculitis: An Update
by: Salem Almaani, et al.
Published: (2021-04-01)

Renal thrombotic microangiopathy in an ANCA-associated vasculitis
by: Ana Teresa Domingos, et al.
Published: (2019-10-01)

Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies
by: Aisling Ui Mhaonaigh, et al.
Published: (2019-11-01)

Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination
by: Saki Okuda, et al.
Published: (2021-07-01)

Development of ANCA-associated vasculitis after COVID-19 in a patient with Lynch syndrome and atypical hemolytic uremic syndrome
by: Fethi Yönet, et al.
Published: (2022-06-01)

Methimazole-Induced ANCA Vasculitis: A Case Report
by: Precil Diego Miranda de Menezes Neves, et al.
Published: (2021-08-01)

COVID-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2018-06-01)

Enho Mutations Causing Low Adropin: A Possible Pathomechanism of MPO-ANCA Associated Lung Injury
by: Feng Gao, et al.
Published: (2016-07-01)

Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
by: Paige K. Marty, et al.
Published: (2022-01-01)

Environmental factors influencing the risk of ANCA-associated vasculitis
by: Wen-Man Zhao, et al.
Published: (2022-09-01)

A Transient Increase in the Serum ANCAs in Patients with SARS-CoV-2 Infection: A Signal of Subclinical Vasculitis or an Epiphenomenon with No Clinical Manifestations? A Pilot Study
by: Monica Gelzo, et al.
Published: (2021-08-01)

Complement Inhibition in ANCA-Associated Vasculitis
by: Vladimir Tesar, et al.
Published: (2022-07-01)

Association of HLA-class II alleles with risk of relapse in myeloperoxidase-antineutrophil cytoplasmic antibody positive vasculitis in the Japanese population
by: Aya Kawasaki, et al.
Published: (2023-03-01)

The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study
by: José Agapito Fonseca, et al.
Published: (2021-05-01)

Favourable outcome of acute hepatitis E infection in patients with ANCA-associated vasculitis
by: Markus Zeisbrich, et al.
Published: (2022-12-01)